News Regeneron preps filings for myasthenia gravis drug Regeneron could be just a few months away from filing for a myasthenia gravis drug that can be dosed just once every three months.
News ASH: Regeneron plays its PNH hand Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.
News GSK claims FDA okay for first oral carbapenem antibiotic GSK has helped top up the antibiotic armamentarium in the US, after securing the first FDA approval for an oral carbapenem, Utebzi.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
